Key points are not available for this paper at this time.
A review. Development of pharmaceutical antagonists of transient receptor potential melastatin 8 (TRPM8) have been pursued for the treatment of chronic pain and migraine. This review focuses on the current state of this progress.
Weyer et al. (Thu,) studied this question.